# Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

> **NCT05192122** · PHASE1 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Discontinue maintenance therapy SOC

## Key facts

- **NCT ID:** NCT05192122
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-31
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192122, "Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05192122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*